Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation

Anaplastic large cell lymphoma (ALCL) is a rare, aggressive, non‐Hodgkin's lymphoma that is characterized by CD30 expression and disease onset in young patients. About half of ALCL patients bear the t(2;5)(p23;q35) translocation, which results in the formation of the nucleophosmin‐anaplastic lymphoma tyrosine kinase (NPM–ALK) fusion protein (ALCL ALK+). However, little is known about the molecular features and tumour drivers in ALK‐negative ALCL (ALCL ALK−), which is characterized by a worse prognosis. We found that ALCL ALK−, in contrast to ALCL ALK+, lymphomas display high miR‐155 expression. Consistent with this, we observed an inverse correlation between miR‐155 promoter methylation and miR‐155 expression in ALCL. However, no direct effect of the ALK kinase on miR‐155 levels was observed. Ago2 immunoprecipitation revealed miR‐155 as the most abundant miRNA, and enrichment of target mRNAs C/EBPβ and SOCS1. To investigate its function, we over‐expressed miR‐155 in ALCL ALK+ cell lines and demonstrated reduced levels of C/EBPβ and SOCS1. In murine engraftment models of ALCL ALK−, we showed that anti‐miR‐155 mimics are able to reduce tumour growth. This goes hand‐in‐hand with increased levels of cleaved caspase‐3 and high SOCS1 in these tumours, which leads to suppression of STAT3 signalling. Moreover, miR‐155 induces IL‐22 expression and suppresses the C/EBPβ target IL‐8. These data suggest that miR‐155 can act as a tumour driver in ALCL ALK− and blocking miR‐155 could be therapeutically relevant. Original miRNA array data are to be found in the supplementary material (Table S1). © 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

[1]  N. Rajewsky,et al.  Regulation of the Germinal Center Response by MicroRNA-155 , 2007, Science.

[2]  Angela G. Fleischman,et al.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. , 2013, Cancer discovery.

[3]  A. Rosenwald,et al.  PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. , 2013, Blood.

[4]  M Paulli,et al.  Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma , 2009, Leukemia.

[5]  W. Ouyang,et al.  Therapeutic opportunities of the IL-22–IL-22R1 system , 2013, Nature Reviews Drug Discovery.

[6]  Johannes Haybaeck,et al.  Reliable Quantification of Protein Expression and Cellular Localization in Histological Sections , 2014, PloS one.

[7]  Stefano Volinia,et al.  Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Ling Tian,et al.  Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. , 2006, Cancer research.

[9]  A. Takaori-Kondo,et al.  B7‐H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma , 2009, Cancer science.

[10]  K. Patel,et al.  Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. , 2014, Human pathology.

[11]  G. Bosma,et al.  Concentration of IgG1 and IgG2a allotypes in serum of nude and normal allotype-congenic mice. , 1980, Journal of immunology.

[12]  S. Cook,et al.  The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. , 2007, Cellular signalling.

[13]  A. Sher,et al.  miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. , 2014, Immunity.

[14]  W. Chan,et al.  STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma , 2014, Haematologica.

[15]  Roberto Piva,et al.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. , 2006, The Journal of clinical investigation.

[16]  J. Renauld,et al.  Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice , 2003, Oncogene.

[17]  R. Greil,et al.  Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphoma , 2010, Proceedings of the National Academy of Sciences.

[18]  Aadel A. Chaudhuri,et al.  Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder , 2008, The Journal of experimental medicine.

[19]  M. Raffeld,et al.  The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up‐regulation in rat la fibroblasts , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[21]  S. Morris,et al.  Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity , 1998, Molecular and Cellular Biology.

[22]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[23]  Stefano A Pileri,et al.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.

[24]  V. Hovestadt,et al.  Genome-wide identification of translationally inhibited and degraded miR-155 targets using RNA-interacting protein-IP , 2013, RNA biology.

[25]  Adam R. Johnson,et al.  Lead identification of novel and selective TYK2 inhibitors. , 2013, European journal of medicinal chemistry.

[26]  S. Turner,et al.  NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. , 2009, Blood.

[27]  David I. Smith,et al.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. , 2011, Blood.

[28]  D. Alexander,et al.  CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. , 2006, Anticancer research.

[29]  S. Pileri,et al.  PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas , 2012, Nature Medicine.

[30]  S. Rutz,et al.  A Genomic Regulatory Element That Directs Assembly and Function of Immune-Specific AP-1–IRF Complexes , 2012, Science.

[31]  Adam R. Johnson,et al.  A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors , 2013, The Journal of Immunology.

[32]  K. Umezawa,et al.  JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. , 2005, Cancer research.

[33]  Ryan M. O’Connell,et al.  Physiological and pathological roles for microRNAs in the immune system , 2010, Nature Reviews Immunology.

[34]  S. Pileri,et al.  Anaplastic large-cell lymphoma. , 2011, Seminars in diagnostic pathology.

[35]  S. Mohammed,et al.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. , 2005, Blood.

[36]  P. Gélébart,et al.  Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma , 2008, Leukemia.

[37]  W. B. van den Berg,et al.  Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. , 2011, Arthritis and rheumatism.

[38]  R. Lai,et al.  Tumorigenesis and Neoplastic Progression IL-21 Contributes to JAK 3 / STAT 3 Activation and Promotes Cell Growth in ALK-Positive Anaplastic Large Cell Lymphoma , 2010 .

[39]  P. Gaulard,et al.  Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. , 2007, Blood.

[40]  K. Elenitoba-Johnson,et al.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. , 2014, Blood.

[41]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[42]  G. Inghirami,et al.  Identification and validation of the anaplastic large cell lymphoma signature. , 2007, Advances in experimental medicine and biology.

[43]  R. Lai,et al.  Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. , 2006, Blood.

[44]  J. Byrd,et al.  Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. , 2012, Cancer research.

[45]  L. Staudt,et al.  Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. , 2012, Blood.

[46]  G. Inghirami,et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.

[47]  K. Maclennan,et al.  Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase , 2003, Oncogene.